BACKGROUND: Epidermal growth factor receptor (EGFR) is coactivated by the μ-opioid
receptor (MOR), expressed on non–small cell lung cancer (NSCLC) cells and human lung …

BACKGROUND: There have been inconsistent reports on whether opioids promote or inhibit
lung cancer growth. In this study, we suggest that opioid growth factor receptor (OGFR), a …

Background Morphine, a µ-opioid receptor (MOR) agonist, has been shown to be related to
the activity of cancer cells, and a higher morphine dosage reduces the survival time of …

Background Recent epidemiologic studies suggesting that there were differences in cancer
recurrence contingent on anesthetic regimens have raised the possibility that μ-opioid …

Morphine, a mu‐opioid receptor (MOR) agonist, has been extensively used to treat
advanced cancer pain. In particular, in patients with cancer metastasis, both morphine and …

Recent epidemiologic studies implying differences in cancer recurrence based on
anesthetic regimens raise the possibility that the mu opioid receptor (MOR) can influence …

BACKGROUND: The possibility that μ opioid agonists can influence cancer recurrence is a
subject of recent interest. Epidemiologic studies suggested that there were differences in …

Background Lung cancer is one of the leading causes of cancer mortalities worldwide, and
non-small cell lung cancer (NSCLC) accounts for the majority of all lung cancer cases …

Opioids promote tumor angiogenesis in mammary malignancies, but the underlying
signaling mechanism is largely unknown. The current study investigated the hypothesis that …

Morphine, a highly potent analgesic agent, is frequently prescribed for moderate to severe
cancer pain. In this study, morphine was administered at a clinically relevant analgesic dose …